Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma

Purpose: The blood–brain barrier (BBB) limits the efficacy of drug therapies for glioblastoma (GBM). Preclinical data indicate that low-intensity pulsed ultrasound (LIPU) can transiently disrupt the BBB and increase intracerebral drug concentrations. Patients and Methods: A first-in-man, single-arm, single-center trial (NCT02253212) was initiated to investigate the transient disruption of the BBB in patients with recurrent GBM. Patients were implanted with a 1-MHz, 11.5-mm diameter cranial ultrasound device (SonoCloud-1, CarThera). The device was activated monthly to transiently disrupt the BBB before intravenous carboplatin chemotherapy. Results: Between 2014 and 2016, 21 patients were registered for the study and implanted with the SonoCloud-1; 19 patients received at least one sonication. In 65 ultrasound sessions, BBB disruption was visible on T1w MRI for 52 sonications. Treatment-related adverse events observed were transient and manageable: a transient edema at H1 and at D15. No carboplatin-related neurotoxicity was observed. Patients with no or poor BBB disruption (n = 8) visible on MRI had a median progression-free survival (PFS) of 2.73 months, and a median overall survival (OS) of 8.64 months. Patients with clear BBB disruption (n = 11) had a median PFS of 4.11 months, and a median OS of 12.94 months. Conclusions: SonoCloud-1 treatments were well tolerated and may increase the effectiveness of systemic drug therapies, such as carboplatin, in the brain without inducing neurotoxicity. See related commentary by Sonabend and Stupp, p. 3750

[1]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Natalia Vykhodtseva,et al.  The kinetics of blood brain barrier permeability and targeted doxorubicin delivery into brain induced by focused ultrasound. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[4]  B. Werner,et al.  Prolonged survival upon ultrasound-enhanced doxorubicin delivery in two syngenic glioblastoma mouse models. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[5]  P. Gutin,et al.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. , 2012, European journal of cancer.

[6]  W. Yung,et al.  Intravenous carboplatin for recurrent malignant glioma: a phase II study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Prados,et al.  Intravenous carboplatin for recurrent gliomas. A dose-escalating phase II trial. , 1996, American journal of clinical oncology.

[8]  D. Levy,et al.  Carboplatin chemotherapy in patients with recurrent high-grade glioma. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[9]  Natalia Vykhodtseva,et al.  Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. , 2012, Cancer research.

[10]  A. Idbaih,et al.  Blood-brain barrier disruption in humans using an implantable ultrasound device: quantification with MR images and correlation with local acoustic pressure. , 2020, Journal of neurosurgery.

[11]  J. Chiras,et al.  Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA) , 1991, Journal of Neuro-Oncology.

[12]  P. Lunardi,et al.  Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study , 2005, Acta Neurochirurgica.

[13]  J. Kuo,et al.  Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment. , 2016, Radiology.

[14]  Edward A. White,et al.  An evaluation of the safety and feasibility of convection-enhanced delivery of carboplatin into the white matter as a potential treatment for high-grade glioma , 2012, Journal of Neuro-Oncology.

[15]  G. Huberfeld,et al.  Safe long-term repeated disruption of the blood-brain barrier using an implantable ultrasound device: a multiparametric study in a primate model. , 2017, Journal of neurosurgery.

[16]  A. Rroji,et al.  Platinum-based Chemotherapy in Recurrent High-grade Glioma Patients: Retrospective Study , 2014, Medical archives.

[17]  K. Hynynen,et al.  Blood‐Brain Barrier Closure Time After Controlled Ultrasound‐Induced Opening Is Independent of Opening Volume , 2017, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[18]  J. Bading,et al.  Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma , 2015, Clinical Cancer Research.

[19]  K. Hoang-Xuan,et al.  Clinical trial of blood-brain barrier disruption by pulsed ultrasound , 2016, Science Translational Medicine.

[20]  Vincent P. Ferrera,et al.  Long-Term Safety of Repeated Blood-Brain Barrier Opening via Focused Ultrasound with Microbubbles in Non-Human Primates Performing a Cognitive Task , 2015, PloS one.

[21]  Thomas C. Chen,et al.  Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. , 2015, JAMA.

[22]  N. McDannold,et al.  Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[23]  K. Hynynen,et al.  Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption. , 2008, Ultrasound in medicine & biology.

[24]  J. Pichler,et al.  A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma , 2014, Clinical Cancer Research.

[25]  J. Chapelon,et al.  Enhanced brain distribution of carboplatin in a primate model after blood–brain barrier disruption using an implantable ultrasound device , 2015, Cancer Chemotherapy and Pharmacology.

[26]  Lorenzo Trippa,et al.  The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? , 2018, Neuro-oncology.

[27]  R Simon,et al.  A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.

[28]  K. Hynynen,et al.  Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. , 2001, Radiology.

[29]  T. Yen,et al.  Focused Ultrasound-Induced Blood–Brain Barrier Opening to Enhance Temozolomide Delivery for Glioblastoma Treatment: A Preclinical Study , 2013, PloS one.

[30]  Manabu Kinoshita,et al.  Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[32]  Fred H. Hochberg,et al.  Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.

[33]  Nir Lipsman,et al.  Blood–brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound , 2018, Nature Communications.

[34]  R Simon,et al.  Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.

[35]  Natalia Vykhodtseva,et al.  Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma. , 2012, Ultrasound in medicine & biology.